Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Correlation of 53BP1 gene mutation with prostatic adenocarcinoma].

Du R, Zheng L, Huang WT, Zhang HZ, Jiang ZM.

Zhonghua Bing Li Xue Za Zhi. 2011 Jul;40(7):449-53. Chinese.

PMID:
22088370
2.

Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high-grade prostatic adenocarcinoma.

Kallakury BV, Jennings TA, Ross JS, Breese K, Figge HL, Fisher HA, Figge J.

Diagn Mol Pathol. 1994 Dec;3(4):227-32.

PMID:
7532528
3.

DNA fingerprint detection of somatic mutations in benign prostatic hyperplasia and prostatic adenocarcinoma.

Werely CJ, Heyns CF, Van Velden DJ, Van Helden PD.

Genes Chromosomes Cancer. 1996 Sep;17(1):31-6.

PMID:
8889504
4.

p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.

Schlechte H, Lenk SV, Löning T, Schnorr D, Rudolph BD, Ditscherlein G, Loening SA.

Eur Urol. 1998;34(5):433-40.

PMID:
9803007
5.

Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer.

Uchida T, Wada C, Shitara T, Egawa S, Koshiba K.

Br J Cancer. 1993 Oct;68(4):751-5.

6.

[Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].

Cao YY, Ge H, Chen LQ, Chen ZF, Wen DG, Li Y, Zhang JH.

Ai Zheng. 2007 Oct;26(10):1052-7. Chinese.

PMID:
17927872
7.

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.

Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW.

Hum Pathol. 1996 Jun;27(6):573-80.

PMID:
8666367
8.

Tumor suppressor gene p53 mutations in human prostate cancer.

Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, et al.

Prostate. 1995 Jul;27(1):18-24.

PMID:
7603913
9.

Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.

Latini JM, Rieger-Christ KM, Wang DS, Silverman ML, Libertino JA, Summerhayes IC.

J Urol. 2001 Nov;166(5):1931-6.

PMID:
11586263
10.

Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.

Mottaz AE, Markwalder R, Fey MF, Klima I, Merz VW, Thalmann GN, Ball RK, Studer UE.

Prostate. 1997 Jun 1;31(4):209-15.

PMID:
9180930
11.

Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.

Yaman O, Ozdiler E, Orhan D, Sak SD, Baltaci S, Tulunay O, Göğüş O.

Urol Int. 1997;58(4):199-202.

PMID:
9253117
12.

Germline alterations in the 53BP1 gene in breast and ovarian cancer families.

Rapakko K, Heikkinen K, Karppinen SM, Erkko H, Winqvist R.

Cancer Lett. 2007 Jan 8;245(1-2):337-40. Epub 2006 Mar 6.

PMID:
16517057
13.

Frequency and characterization of p53 mutations in clinically localized prostate cancer.

Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW.

Urology. 1995 Mar;45(3):470-5.

PMID:
7879337
14.

Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.

Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P.

Am J Pathol. 1995 Jul;147(1):92-101.

15.

[Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].

Zeng X, Wu SF, Xu Q, Xiao Y, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Sep;35(9):523-8. Chinese.

PMID:
17134545
16.

Retinoblastoma gene mutations in primary human prostate cancer.

Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T.

Prostate. 1995 Dec;27(6):314-20.

PMID:
7501543
17.

Common genetic variants in 53BP1 associated with nonsmall-cell lung cancer risk in Han Chinese.

Zhang H, Hao S, Zhao J, Zhou B, Ren Y, Yan Y, Zhao Y.

Arch Med Res. 2014 Jan;45(1):84-9. doi: 10.1016/j.arcmed.2013.10.011. Epub 2013 Dec 6.

PMID:
24316395
19.

Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.

Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, Rustgi AK.

Pancreas. 1996 Jan;12(1):10-7.

PMID:
8927612
20.

Association of p53 mutations with metastatic prostate cancer.

Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC.

Clin Cancer Res. 1995 Oct;1(10):1111-8.

Supplemental Content

Support Center